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Abstract 
Introduction: Recent data have shown that diabetic kidney disease (DKD) is associated 
with abnormal gut microbiota composition. Zonulin is a physiological tight junction 
modulator and an intestinal permeability marker. In this study we aimed to investigate 
serum levels of zonulin and interleukin 6 (IL-6) in patients with type 2 diabetes mellitus 
(T2DM) and different levels of albuminuria.  
Material and methods: Ninety patients with T2DM and 30 healthy controls (HC) aged 
between 18 and 65 years were enrolled in the study. T2DM patients were divided into 
three groups as patients with normoalbuminuria (n = 30), microalbuminuria (n = 30), and 
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macroalbuminuria (n = 30). Serum zonulin and IL-6 levels were measured by ELISA 
method. 
Results: There was no significant difference between groups in terms of age, gender, 
serum ALT, LDL-C, HDL-C, and zonulin levels (p > 0.05). Significant differences 
between groups were present for the duration of diabetes (p < 0.001), body mass index (p 
< 0.001), fasting blood glucose (p < 0.001), creatinine (p < 0.001), uric acid (p = 0.037), 
triglyceride (p = 0.003), total cholesterol (p < 0.001), glycated haemoglobin (p < 0.001), 
and IL-6 (p < 0.001) levels. IL-6 levels were significantly increased in the 
microalbuminuria and macroalbuminuria groups compared to the HC group, but no 
significant difference was determined between the HC and normoalbuminuria group. In 
patients with diabetic kidney disease, a significant positive correlation was found between 
zonulin with IL-6 and proteinuria (rho = 0.296, p = 0.008; rho = 0.190, p < 0.047, 
respectively). The serum IL-6 level was positively correlated with microalbuminuria and 
proteinuria (rho = 0.451, p < 0.001; rho = 0.425, p < 0.001, respectively).   
Conclusions: We suggest that the serum zonulin level is not a promising biomarker to 
assess the severity of DKD in patients with long-standing T2DM. 




Diabetic kidney disease (DKD), one of the major microvascular complications of diabetes 
mellitus (DM), is the leading cause of chronic kidney disease (CKD) and end-stage renal 
disease. DKD develops in approximately one-third of all DM patients [1]. The 
pathogenesis of DKD is a multifactorial and complex process. Hyperglycaemia, 
hypertension, hyperlipidaemia, obesity, ethnicity, and genetic predisposition are 
responsible for DKD development and progression [2]. In addition, inflammation 
together with oxidative stress and fibrosis are also key factors in the progression of DKD 
[3]. Recently, intestinal microbiota was blamed for chronic inflammation in DM and 
chronic kidney patients [4-5]. 
CKD patients may have altered intestinal microbiota composition (dysbiotic gut) 
due to the slowed intestinal transit time, decreased digestive capacity, and secretion of 
ammonia and urea into the gut [4]. Recent evidence suggests that this dysbiotic gut causes 
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production of major uremic toxins such as indoxyl sulphate, p-cresyl sulphate, indoxyl 
sulphate, and trimethylamine-N-oxide, which might be linked to the progression of CKD 
[2]. On the other hand, gut microbiota alteration was shown to affect the development of 
proteinuria, hypertension, inflammation, and diabetes mellitus. In this respect, it is 
thought that there is a vicious cycle between CKD formation and gut microbiota [6]. 
Zonulin is a 47 kDa protein, which is encoded by the haptoglobin gene and 
regulates paracellular transport by modulation of enterocyte tight junctions. Upregulation 
of zonulin by triggering factors (gluten, increased fatty acid, etc.) leads to disassembly of 
tight junctions, uncontrolled antigen trafficking from the intestinal lumen to submucosa, 
and consequently altered intestinal permeability, which gives rise to chronic 
inflammatory diseases [7–8]. Zonulin expression is suggested to be controlled by a 
proinflammatory cytokine interleukin 6 (IL-6) via STAT3 activation and miR-18a 
induction [9]. In recent years various studies have shown that circulatory zonulin levels 
are elevated in several metabolic and inflammatory diseases such as insulin resistance, 
obesity, metabolic syndrome, T1DM, and T2DM [10–13]. 
In this study we aimed to evaluate serum levels of zonulin as an intestinal 
permeability marker and IL-6 as an inflammation marker in relatively long-standing 
T2DM patients with and without DKD, to investigate correlations with metabolic and 
biochemical parameters. 
 
Material and methods 
This cross-sectional study was approved by the Ethics Committee of the Faculty of 
Medicine (16.04.2019-137) and conducted in accordance with the Helsinki Declaration. 
All participants gave verbal and written informed consent prior to participation in the 
study. 
 
Patients and control subjects 
A total of 120 participants (78 female, 42 male) between the ages of 18 and 65 years were 
recruited in this study from the Endocrine and Metabolism Outpatient Clinic. 
 A healthy control group of 30 subjects without T2DM (HC; n = 30) and 90 patients 
with T2DM were included in the study. Type 2 diabetic patients were grouped according 
to urinary albumin as normoalbuminuria (< 30 mg/24 hour; n = 30), microalbuminuria 
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(30–300 mg/24 hour; n = 30), and macroalbuminuria groups (>300 mg/24 hour; n = 30). 
Exclusion criteria included the presence of T1DM, pregnancy, acute or chronic infectious 
disease, rheumatological disease, hepatic disease, gastrointestinal disease, cancer, and 
regular usage of anti-inflammatory drugs. The HC group was randomly selected from 
people without any systemic disease or drug use. At the time of recruitment, the body 
weight and height of all participants were measured, and body mass index (BMI) was 
calculated as weight/height2 and expressed in kilograms per square metre (kg/m2). 
Systolic/diastolic blood pressure measurements were also performed. Blood pressure 
measurements were performed according to European Society of Cardiology (ESC)-
European Society of Hypertension (ESH) guidelines on hypertension [14]. Age, sex, time 
since diagnosis of DM (duration of DM), and existence of micro- and macrovascular 
complications of T2DM were also recorded. 
 
Sample collection and biochemical measurements 
All biochemical analyses were performed at the Medical Biochemistry 
Laboratory. Venous blood samples were collected after a minimum of eight hours fasting 
for glycated haemoglobin (HbA1c), routine chemistry analysis, and zonulin and IL-6 
measurements. Also, 24-hour urine samples were collected by participants for urinary 
protein, microalbumin, and creatinine measurement. HbA1c was determined by high-
performance liquid chromatography method (Bio-Rad Co, CA, USA) from blood 
collection tubes containing EDTA. Serum specimens were separated after centrifuge of 
clot activator blood collection tubes at 3000 rpm for 10 minutes. On the same day of the 
blood collection, serum fasting blood glucose, alanine aminotransaminase (ALT), 
creatinine, uric acid, triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), 
total cholesterol (TC), and 24-hour urine protein and albumin were measured on a 
Beckman Coulter AU 5800 chemistry analyser (Beckman Coulter, Brea, USA). The 
Friedewald formula: LDL-C = TC-(HDL-C + (TG/5)), was used for low-density 
lipoprotein cholesterol (LDL-C) calculation, and the glomerular filtration rate (GFR) was 
estimated with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 
equation [15]. Serum samples were portioned into Eppendorf tubes and frozen at –80º 
until analysis of serum zonulin and IL-6 levels. Commercial human enzyme-linked 
immunosorbent assay (ELISA) kits were used for the determination of serum zonulin and 
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IL-6 levels (E-EL-H5560, E-EL-H0102; Elabscience, Wuhan, China). Detection limits of 
the ELISA tests were 0.47 ng/mL and 4.69 pg/mL, respectively.  
 
Statistical analyses 
All statistical analyses were performed using SPSS version 22 (SPSS Inc., 
Chicago, IL, USA). The χ2 test was used to compare categorical data. The continuous 
variables were investigated using the Shapiro-Wilk normality test. Parameters with 
normal distribution were compared with one-way analysis of variance (ANOVA) 
followed by Tukey HSD post-hoc test, and parameters with non-normal distribution were 
compared using the Kruskal-Wallis test followed by Mann-Whitney U test. Correlations 
between parameters were evaluated with Spearman’s correlation analysis. A p value of 
less than 0.05 was considered to show a statistically significant result.  
 
Results 
A total of 90 T2DM patients (30 patients with normoalbuminuria, 30 patients with 
microalbuminuria, 30 patients with macroalbuminuria) and 30 HC were included in this 
study. Demographic, clinical, and laboratory parameters and statistical results for 
comparisons of the groups are shown in Table 1. There was no significant difference 
between groups for age, gender, serum ALT, LDL-C, HDL-C, and zonulin levels 
(p>0.05). Significant differences between groups were present for duration of diabetes (p 
< 0.001), BMI (p < 0.001), fasting blood glucose (p < 0.001), creatinine (p < 0.001), uric 
acid (p = 0.037), TG (p = 0.003), TC (p < 0.001), HbA1c (p < 0.001), and IL-6 (p < 0.001) 
levels. IL-6 levels were significantly increased in both micro and macro albuminuria 
groups of DKD patients compared to the HC group, but no significant difference was 
determined between HC and normoalbuminuria group (Table, Figure 1, Figure 2). In 
patients with DKD, a significant positive correlation was found between zonulin with IL-
6 and proteinuria (rho = 0.296, p = 0.008; rho = 0.190, p = 0.047, respectively). Serum 
IL-6 level was positively correlated with albuminuria and proteinuria (rho = 0.451, p < 
0.001; rho = 0.425, p < 0.001). 
There was no significant difference between the use of antidiabetic (except 
insulin) and antihyperlipidemic medications among diabetic patients. Regarding 
medications, most of the patients (74%) were taking metformin, and approximately half 
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of the patients (46%) were on insulin therapy. Other medications and the percentages of 
patients using them were as follows; glucagon-like peptide (GLP) analogues or dipeptidyl 
peptidase 4 (DPP4) inhibitors (45%), sulphonylurea (26%), sodium-glucose co-




The present study assessed the serum zonulin and IL-6 levels in cases with long 
history of T2DM and their possible association with the presence and severity of 
albuminuria. Although serum IL-6 levels were significantly increased in DKD patients 
when compared to both HC and normoalbuminuria groups, the zonulin levels were not 
significantly different between the groups. Interleukin 6 levels were simultaneously 
increased with the progression of DKD, which may represent the role of chronic 
inflammation in the pathogenesis of DKD. 
In the literature, two studies that evaluated newly diagnosed T2DM patients 
showed increased serum zonulin levels [12, 13]. Zhang et al. showed a progressive 
increase in serum zonulin level with the impairment of glucose tolerance and significantly 
high levels in DM patients [12]. Jayashree et al. found that serum levels of 
lipopolysaccharide, IL-6, tumour necrosis factor-alpha, and zonulin were significantly 
increased in the newly diagnosed T2DM group compared to the healthy group [13]. In 
our study significant increases in IL-6 levels were observed in the micro- and 
macroalbuminuria (DKD positive) groups. On the other hand, although the zonulin levels 
tended to increase with the progression of DKD, the difference was not significant 
between the groups. Our results are partly consistent with the literature because the IL-6 
levels simultaneously increased with the progression of DM. Our findings regarding 
zonulin contradict the studies of Zhang et al. and Jayashree et al., and this contradiction 
may be due initially to the duration of diabetes as our diabetic patients were diagnosed 
for a relatively long period and prescribed antidiabetic drugs for that period, but the 
diabetic groups in the mentioned studies were newly diagnosed. Secondly, human gut 
microbiota composition is extremely variable between individuals, and therapies such as 




There are several studies that reported abnormal gut microbiota in uncomplicated 
and complicated T1DM patients with advanced stages of DKD. Winther et al. reported 
significant differences in both gut microbiota and plasma metabolome according to the 
severity of DKD [18]. In an experimental study, it was shown that phenyl sulphate, 
originating from the gut microbiota of rats, causes diabetic kidney disease in rats. When 
tyrosine phenol-lyase enzyme, which ensures the formation of phenyl sulphate, is 
inhibited albuminuria was shown to decrease [19]. 
In another study, performed by Al-Obaide et al., serum trimethylamine-N-oxide, 
lipopolysaccharide, zonulin, and IL-6 levels were shown to be increased in T2DM 
patients with advanced kidney disease [glomerular filtration rate (GFR) < 30 mL/min] 
compared to healthy controls [20]. In our study the T2DM patients were classified by 
their albuminuria levels, but the GFR levels in our groups were mildly impaired because 
macroalbuminuria group had the lowest median GFR value of 74 mL/min and the highest 
serum creatinine levels with a median value of 1.15 mg/dL (Tab. 1).  
In a study by Hasslatcher et al. 63 diabetic patients were studied with a mean of 
13 years duration. Zonulin levels of diabetic patients were higher than healthy controls, 
and zonulin concentrations were correlated with BMI and HbA1c [21]. Contrary to this 
study, we found no significant difference between the zonulin levels of healthy control 
and 90 T2DM patients with a mean of 10 years duration. In our study zonulin levels 
correlated only with IL-6 and urinary protein excretion, but there was no correlation 
between the other factors (GFR, creatinine, BMI). Another study by Dschietzig et al. 
speculated that the plasma zonulin level can decrease with urine excretion and observed 
inverse associations of zonulin with creatinine in T2DM. They claimed that urinary 
zonulin excretion may increase in parallel with the severity of DKD because zonulin is a 
smaller protein than albumin [22]. In our study, we did not measure zonulin excretion in 
urine, but there was a positive relationship between the intensity of protein excretion and 
serum zonulin levels, although it did not reach statistical significance between the groups.  
In our study, when diabetics with mainly albuminuria (micro- and 
macroalbuminuria) (n = 60) and the healthy group were evaluated in terms of zonulin and 
IL-6 levels, there was no difference in zonulin, but IL-6 levels increased significantly. 
The IL-6 levels were positively correlated with blood glucose, HbA1c, BMI, TG, 
creatinine levels, urinary albumin, and protein excretion and negatively correlated with 
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GFR. As anticipated, during DKD progression the level of fasting glucose, HbA1c, and 
creatinine levels steadily increased and GFR decreased over the years due to the long-
term exposure to high glucose levels increasing the risk of vascular damage to kidney 
cells. Significantly higher levels of IL-6 were found in the macroalbuminuria group 
compared to the HC and normoalbuminuria groups; however, inflammation and diabetic 
kidney disease progression was not related with serum zonulin concentration.  
Our study has certain limitations. First, we did not assess the microbiota 
composition. Second, uremic toxin analysis was not performed, and third, the absence of 
dietary information of patients is an additional limitation. 
 
Conclusions 
We suggest that the serum zonulin level is not a promising biomarker to assess the 
severity of DKD in patients with long-standing T2DM. 
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Table 1. Demographic, clinical, and biochemical characteristics of the groups (n = 120) 












20/10 18/12 20/10 20/10 0.932 
Age [years] 56.0 ± 5.9 53.5 ± 8.1 54.8 ± 6,6 55.5 ± 8.2 0.564 
Duration [years] 0 8.4 ± 6.6a 7.7 ± 6.2a 15.3 ± 8.5a–c < 0.001 
BMI [kg/m2] 28.1 ± 3.6 30.4 ± 4.6 33.1 ± 5.6a 33.3 ± 7.2a < 0.001 
FBG [mg/dL] 93.5 (11) 156 (80.5)a 157 (93.5)a 199.5 (149.5)a, b < 0.001 
HbA1c (%) 5.5 (0.5) 7.6 (2.4)a 8.2 (3.9)a 9.6 (4.4)a < 0.001 
ALT [mg/dL] 18.5 (9.5) 19.5 (14.5) 21.0 (12.0) 19.0 (8.5) 0.167 
TG [mg/dL] 109.5 (83) 138.0 (108.8) 141.5 (65.0) 181.0 (267.3)a–c 0.003 
TC [mg/dL] 209.5 (59.8) 212.5 (45.0) 195.5 (44.0) 245.2 (105.5)a–c < 0.001 
LDL-C [mg/dL] 134.0 ± 29.4 124.6 ± 24.5 116.2 ± 30 131.6 ± 51.3 0.206 
HDL-C [mg/dL] 48.5 (16.0) 48.0 (18.5) 44.0 (11.0) 45.5 (20.0) 0.060 
Uric acid [mg/dL] 4.9 (2.1) 5.0 (1.3) 5.2 (2.4) 6.5 (1.9)a–c 0.037 
Cr [mg/dL] 0.85 (0.25) 0.88 (0.17) 0.90 (0.15) 1.15 (0.53)a–c < 0.001 
GFR [ml/min] 92.0 (10.8) 85.5 (28.5) 86.0 (32.8) 74.0 (40.8)a–c < 0.001 
Protein [g/24 h] 0.08 (0.04) 0.10 (0.05) 0.19 (0.16)a, b 1.30 (2.3)a–c < 0.001 
Alb [mg/24 h] 2.35 (5.85) 9.8 (10.2)a 64.5 (80.8)a, b 678.5 (685.8)a–c < 0.001 
Zonulin [ng/mL] 101.8 (115.5) 107.1 (101.9) 115.4 (75.0) 116.5 (156.8) 0.580 
IL-6 [pg/mL] 5.02 (11.0) 5.03 (10.3) 14.08 (12.6)a, b 16.8 (13.7)a, b < 0.001 
Normal distributed data are given as mean ± SD, non-normal distributed data are given as median 
(IQR). Bold values are statistically significant (p < 0.05). asignificant difference when compared 
to HC. bsignificant difference when compared to the normoalbuminuria group. csignificant 
difference when compared to the microalbuminuria group. 
BMI — body mass index; FBG — fasting blood glucose; TG — triglyceride; TC — total 
cholesterol; LDL-C — low-density lipoprotein; HDL-C — high-density lipoprotein; Cr — 
creatinine; GFR — glomerular filtration rate; Alb — albumin; IL-6 — interleukin 6 
 
 






Figure 2. Serum interleukin 6 (IL-6) levels in study groups  
 
    
 
